09:47 AM EST - Medicago Inc. : announced that a single low dose of its pandemic vaccine formulated for the H5N1 Indonesia strain of Avian flu provided 100% cross-protection in ferrets against a lethal challenge with the highly virulent Vietnam Influenza virus. H5N1 vaccines are known to require repeated administrations to elicit an antibody response. Medicago is believed to be the first company to demonstrate full cross-protection in a heterogeneous challenge with only a single dose of its H5N1 vaccine in the ferret model. Medicago Inc.
shares T.MDG are trading up $0.005 at $0.37.
